The company's approach focuses on the barrier-enhancing effects of azithromycin and uses a non-antibiotic macrolide platform to address epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases. Their lead drug candidate, EP395, aims to be the first on-market oral, disease-modifying, non-antibiotic, barrier-strengthening, and anti-inflammatory macrolide for COPD and other inflammatory airway diseases. Founded in 2014, EpiEndo Pharmaceuticals is an Icelandic clinical-stage pharmaceutical company with a unique focus on the impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract, and skin.